Cellular therapies, growth factors, miRNA, and new biomaterials show promise for treating acute myocardial infarction, though current clinical effects remain modest.
Modest effects of cell therapy in AMI warrant continued caution against routine use; leaves open potential for refined modalities in future trials.
Progress has been made into research on new therapies, mechanical and pharmacological approaches and repair/regenerative cellular therapy to treat irreversible cardiovascular pathologies, such as acute myocardial infarction. Research into cellular therapies is exploring the use of new cellular types. Although the therapeutic effects of cell therapy remain modest, results from clinical trials are encouraging. To expand this improvement, advances are being made that involve the paracrine function of stem cells, the use of growth factors, miRNA and new biomaterials. In the near future, these therapies should become part of routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Itier et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: